down arrow

Hikma Pharmaceuticals Plc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B0LCW083
  • LON: HIK
GBP
16.06
-0.05 (-0.31%)

Sep 22

LON

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Hikma Pharmaceuticals Plc
HUTCHMED (China) Ltd.
GSK Plc
AstraZeneca PLC
Indivior PLC
Dechra Pharmaceuticals Plc
Alliance Pharma Plc
Benchmark Holdings Plc

Why is Hikma Pharmaceuticals Plc ?

1
Flat results in Jun 26
  • OPERATING CASH FLOW(Y) Lowest at GBP 642.12 MM
  • RAW MATERIAL COST(Y) Grown by 7.2% (YoY)
  • DEBT-EQUITY RATIO (HY) Highest at 66.11 %
2
With ROE of 14.54%, it has a very expensive valuation with a 1.70 Price to Book Value
  • Over the past year, while the stock has generated a return of -1.65%, its profits have fallen by -11.1%
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -1.65% returns in the last 1 year, the stock has also underperformed FTSE 100 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hikma Pharmaceuticals Plc for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Hikma Pharmaceuticals Plc
-1.65%
-1.06
35.73%
FTSE 100
16.06%
1.36
11.82%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
6.85%
EBIT Growth (5y)
-0.23%
EBIT to Interest (avg)
6.58
Debt to EBITDA (avg)
1.54
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
0.80
Tax Ratio
23.29%
Dividend Payout Ratio
45.19%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
16.14%
ROE (avg)
16.01%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.70
EV to EBIT
9.70
EV to EBITDA
7.06
EV to Capital Employed
1.48
EV to Sales
1.64
PEG Ratio
NA
Dividend Yield
1.35%
ROCE (Latest)
15.24%
ROE (Latest)
14.54%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
DIVIDEND PER SHARE(HY)

Highest at GBP 3.08

NET SALES(Q)

Highest at GBP 1,284.6 MM

-7What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at GBP 642.12 MM

RAW MATERIAL COST(Y)

Grown by 7.2% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 66.11 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.77 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.08 times

DIVIDEND PER SHARE(HY)

Lowest at GBP 3.08

Here's what is working for Hikma Pharmaceuticals Plc

Dividend per share
Highest at GBP 3.08 and Grown
In each year in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (GBP)

Net Sales
Highest at GBP 1,284.6 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (GBP MM)

Depreciation
Highest at GBP 90.7 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (GBP MM)

Here's what is not working for Hikma Pharmaceuticals Plc

Operating Cash Flow
Lowest at GBP 642.12 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (GBP MM)

Debt-Equity Ratio
Highest at 66.11 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio
Lowest at 1.77 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 3.08 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Dividend per share
Lowest at GBP 3.08
in the last five years
MOJO Watch
Company is distributing lower dividend than previous years

DPS (GBP)

Raw Material Cost
Grown by 7.2% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading